133 related articles for article (PubMed ID: 36181042)
1. Factors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience.
Cimen F; Agackiran Y; Düzgün S; Aloglu M; Senturk A; Atikcan S
Medicine (Baltimore); 2022 Sep; 101(39):e30711. PubMed ID: 36181042
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
Lococo F; Rena O; Torricelli F; Filice A; Rapicetta C; Boldorini R; Paci M; Versari A
Interact Cardiovasc Thorac Surg; 2020 Apr; 30(4):593-596. PubMed ID: 32003806
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
[TBL] [Abstract][Full Text] [Related]
4. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of pretreatment volume-based quantitative
Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
8. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
9. Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
Doi H; Kuribayashi K; Kitajima K; Yamakado K; Kijima T
Clin Lung Cancer; 2020 Jan; 21(1):66-74.e2. PubMed ID: 31551134
[TBL] [Abstract][Full Text] [Related]
10. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
[TBL] [Abstract][Full Text] [Related]
11. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive role of [
Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
[TBL] [Abstract][Full Text] [Related]
14.
Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.
Zhang Y; Li R; Gu Y; LiZhu Y; Liu X; Zhang S
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557076
[No Abstract] [Full Text] [Related]
16. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
17. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
18. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
Francis RJ; Segard T; Morandeau L; Lee YC; Millward MJ; Segal A; Nowak AK
Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
Tsutani Y; Takuwa T; Miyata Y; Fukuoka K; Hasegawa S; Nakano T; Okada M
Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
[TBL] [Abstract][Full Text] [Related]
20. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
